Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CASP2 | P42575 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9508397 | 0.87 | CASP2 (0.39) | TSHRCYP3A4CYP2D6CYP2C19LMNA | |
| SCHEMBL9505929 | 0.87 | CA1 (0.43) | TSHRLMNACA1CA2CA9 | |
| SCHEMBL21326872 | 0.84 | CYP2C19 (0.33) | TSHRCYP3A4CYP2D6CYP2C19LMNA | |
| SCHEMBL9506141 | 0.84 | CASP2 (0.46) | TSHRCYP3A4CYP2D6CYP2C19LMNA | |
| SCHEMBL9506124 | 0.84 | SLC6A5 (0.51) | CYP3A4CYP2D6LMNAMEN1KMT2A | |
| SCHEMBL3548845 | 0.83 | ALDH1A1 (0.54) | TSHRCYP3A4CYP2D6CYP2C19LMNA | |
| SCHEMBL16227684 | 0.82 | TSHR (0.43) | TSHRCYP2D6LMNACA1CA2 | |
| SCHEMBL14547392 | 0.82 | CASP2 (0.48) | TSHRLMNAALDH1A1HPGDSLC6A5 | |
| SCHEMBL15684647 | 0.82 | TDP1 (0.44) | CYP3A4CA1CA2CA9MEN1 | |
| SCHEMBL6319788 | 0.81 | CA2 (0.38) | TSHRLMNACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1056 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20210060040-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | claimed |
| EP-3534933-A1 | BETA-ALETHINE, IMMUNE MODULATORS, AND USES THEREOF | Aximmune, Inc. (US) | 2019-09-11 | — | — | EP | claimed |
| CN-109069470-A | Use of specific benzodihydrofuran lignans for inhibiting breast cancer cell metastasis | 杨宁荪 | 2018-12-21 | — | — | CN | claimed |
| US-20170304327-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | claimed |
| EP-3187184-A1 | COMBINATION THERAPIES FOR HEMATOLOGIC MALIGNANCIES | Gilead Calistoga LLC (US) | 2017-07-05 | — | — | EP | claimed |
| US-20170119771-A1 | COMBINATION THERAPIES FOR HEMATOLOGIC MALIGNANCIES | GILEAD SCIENCES, INC. | 2017-05-04 | — | — | US | claimed |
| CN-106163524-A | 7-benzyl-4- (2-methylbenzyl) -2,4,6,7,8, 9-hexahydroimidazo [1,2-a ] pyrido [3,4-e ] pyrimidin-5 (1H) -one, salts thereof, and methods of use | 昂克希尔迪克斯有限公司 | 2016-11-23 | — | — | CN | claimed |
| EP-2683377-A1 | COMBINATION THERAPIES FOR HEMATOLOGIC MALIGNANCIES | Gilead Calistoga LLC (US) | 2014-01-15 | — | — | EP | claimed |
| US-8540967-B2 | Porphyrazine optical and dual optical/MR contrast and therapeutic agents | HOFFMAN/BARRETT, L.L.C. (US) | 2013-09-24 | — | — | US | claimed |
| JP-3319597-B2 | — | — | 2002-09-03 | — | — | JP | claimed |
| EP-0636022-A1 | CHEMICAL PREVENTION OR REVERSAL OF CATARACT BY PHASE SEPARATION INHIBITORS | OCULON CORPORATION (US) | 1995-02-01 | — | — | EP | claimed |
| WO-1994026259-A1 | CHEMICAL PREVENTION OR REVERSAL OF CATARACT BY PHASE SEPARATION INHIBITORS | OCULON CORPORATION (US) | 1994-11-24 | — | — | WO | claimed |
| EP-0539525-A4 | — | — | 1994-01-12 | — | — | EP | claimed |
| WO-1993020805-A1 | CHEMICAL PREVENTION OR REVERSAL OF CATARACT BY PHASE SEPARATION INHIBITORS | OCULON CORPORATION (US) | 1993-10-28 | — | — | WO | claimed |
| EP-0432000-B1 | REDUCING COMPOSITION FOR PERMANENT HAIRWAVING, COMPRISING AS REDUCING AGENT AN AMINO-MERCAPTOALKYLAMIDE OR ONE OF ITS SALTS, AND ITS USE IN A PROCESS FOR PERMANENT HAIRWAVING | L'OREAL (FR) | 1993-08-11 | — | — | EP | claimed |
| EP-0538330-A4 | BETA-ALETHINE USE IN CELL CULTURE AND THERAPY | — | 1993-07-07 | — | — | EP | claimed |
| EP-0539525-A1 | VITALETHEINE AND USE IN CELL CULTURE AND THERAPY | UNIVERSITY OF NEW MEXICO (US) | 1993-05-05 | — | — | EP | claimed |
| EP-0538330-A1 | BETA-ALETHINE USE IN CELL CULTURE AND THERAPY. | UNIV NEW MEXICO (US) | 1993-04-28 | — | — | EP | claimed |
| WO-1992000960-A1 | BETA-ALETHINE USE IN CELL CULTURE AND THERAPY | UNIVERSITY OF NEW MEXICO (US) | 1992-01-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119771-A1 | COMBINATION THERAPIES FOR HEMATOLOGIC MALIGNANCIES | BCL6, HCLS1, MCL1 | TSHR 3369/4885CYP3A4 4397/4885CYP2D6 3768/4885 |
| US-20210060040-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | TSHR 784/4885CYP3A4 1213/4885CYP2D6 800/4885 |
| US-20170304327-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | TSHR 784/4885CYP3A4 1213/4885CYP2D6 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.